FGFR1 Amplification

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
FGFR1 Amplification	Infigratinib	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID1911 Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated wi… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
Bone Ewing Sarcoma1
FGFR1 Amplification	Ponatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID1247 116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis,… (full text at CIViC) PMID 26179511 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Bladder Carcinoma1

FGFR1 Amplification

Infigratinib

Predictive

Does Not Support Sensitivity Response

accepted

EID1911

Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated wi… (full text at CIViC)

PMID 27870574 · Nogova et al., 2017 · Open in CIViC

civic

Bone Ewing Sarcoma1

FGFR1 Amplification

Ponatinib

Predictive

Supports Sensitivity Response

accepted

EID1247

116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis,… (full text at CIViC)

PMID 26179511 ·

Lung Non-Small Cell Carcinoma3
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Better Outcome	2	accepted	EID684 This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general. PMID 23806793 · Tran et al., 2013 · Open in CIViC	civic
FGFR1 Amplification	Dovitinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID3027 Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partia… (full text at CIViC) PMID 27315356 · Lim et al., 2016 · Open in CIViC	civic
FGFR1 Amplification	PD173074	Predictive	D	Supports Sensitivity Response	4	accepted	EID686 Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line. PMID 21666749 · Dutt et al., 2011 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma3

FGFR1 Amplification

(prognostic)

Prognostic

Supports Better Outcome

accepted

EID684

This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.

PMID 23806793 · Tran et al., 2013 · Open in CIViC

civic

FGFR1 Amplification

Dovitinib

Predictive

Supports Sensitivity Response

accepted

EID3027

Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partia… (full text at CIViC)

PMID 27315356 · Lim et al., 2016 · Open in CIViC

civic

FGFR1 Amplification

PD173074

Predictive

Supports Sensitivity Response

accepted

EID686

Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.

PMID 21666749 · Dutt et al., 2011 · Open in CIViC

civic

Lung Squamous Cell Carcinoma6
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID682 In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates w… (full text at CIViC) PMID 23182986 · Kim et al., 2013 · Open in CIViC	civic
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID683 This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis. PMID 25086725 · Seo et al., 2014 · Open in CIViC	civic
FGFR1 Amplification	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	4	accepted	EID687 Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metas… (full text at CIViC) PMID 25433983 · Jiang et al., 2015 · Open in CIViC	civic
FGFR1 Amplification	Infigratinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1908 Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). In the subgroup of FGFR1-amplified squamous NSCLC (as classified by FISH), 36 patients were trea… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
FGFR1 Amplification	PD173074	Predictive	D	Supports Sensitivity Response	5	accepted	EID680 Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were hig… (full text at CIViC) PMID 21160078 · Weiss et al., 2010 · Open in CIViC	civic
FGFR1 Amplification AND MYC Overexpression	Pazopanib	Predictive	C	Supports Sensitivity Response	2	accepted	EID7811 Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC. Patient was treated with 400 mg pazopanib twice a day. CT taken four and… (full text at CIViC) PMID 24302556 · Malchers et al., 2014 · Open in CIViC	civic

Lung Squamous Cell Carcinoma6

FGFR1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID682

In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates w… (full text at CIViC)

PMID 23182986 · Kim et al., 2013 · Open in CIViC

civic

FGFR1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID683

This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis.

PMID 25086725 · Seo et al., 2014 · Open in CIViC

civic

FGFR1 Amplification

(prognostic)

Prognostic

Does Not Support Poor Outcome

accepted

EID687

Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metas… (full text at CIViC)

PMID 25433983 · Jiang et al., 2015 · Open in CIViC

civic

FGFR1 Amplification

Infigratinib

Predictive

Supports Sensitivity Response

accepted

EID1908

Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). In the subgroup of FGFR1-amplified squamous NSCLC (as classified by FISH), 36 patients were trea… (full text at CIViC)

PMID 27870574 · Nogova et al., 2017 · Open in CIViC

civic

FGFR1 Amplification

PD173074

Predictive

Supports Sensitivity Response

accepted

EID680

Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were hig… (full text at CIViC)

PMID 21160078 · Weiss et al., 2010 · Open in CIViC

civic

FGFR1 Amplification AND MYC Overexpression

Pazopanib

Predictive

Supports Sensitivity Response

accepted

EID7811

Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC. Patient was treated with 400 mg pazopanib twice a day. CT taken four and… (full text at CIViC)

PMID 24302556 · Malchers et al., 2014 · Open in CIViC

civic

Malignant Breast Neoplasm21
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	5	accepted	EID12486 PALOMA-3, a phase III, multicenter, double-blind randomized controlled trial enrolled patients with advanced estrogen receptor-positive breast cancer receiving fulvestrant (estrogen receptor antagonis… (full text at CIViC) PMID 32940689 · O'Leary et al., 2021 · Open in CIViC	civic
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID12487 This study aimed to determine the amplification rates of FGFR1, FGFR2, and FGFR3 in breast cancer and evaluate their impact on prognosis. In a cohort of 894 breast cancer patients, FGFR1 amplification… (full text at CIViC) PMID 32852708 · Erber et al., 2020 · Open in CIViC	civic
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	5	accepted	EID12497 Amplification of FGFR1 is one molecular alteration associated with hormonal resistance and relapse in breast cancer. Using two different patient data cohorts (H12O - patients diagnosed at Hospital 12 … (full text at CIViC) PMID 33579347 · Mouron et al., 2021 · Open in CIViC	civic
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID12532 In a cohort of 100 patients with metastatic breast cancer, FGFR1 Amplification was found in 20 cases via FISH, with 17 cases classified as amplified and three cases as low amplified using published cr… (full text at CIViC) PMID 32517171 · Bourrier et al., 2020 · Open in CIViC	civic
FGFR1 Amplification	Afimoxifene	Predictive	D	Supports Resistance	3	accepted	EID1105 FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1. PMID 20179196 · Turner et al., 2010 · Open in CIViC	civic
FGFR1 Amplification	Dovitinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID1604 Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC	civic
FGFR1 Amplification	Dovitinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID12478 Dovitinib, a pan-FGFR small molecular inhibitor, has shown activity in pre-clinical models against FGFR-expressing breast cancer model cell lines, as well as as in a single agent in a phase II clinica… (full text at CIViC) PMID 28183331 · Musolino et al., 2017 · Open in CIViC	civic
FGFR1 Amplification	Endocrine Drug Therapy + EverolimusCombination	Predictive	B	Supports Sensitivity Response	3	accepted	EID12498 In a clinical cohort of patients with HR+/HER2- metastatic breast cancer (n=110), FGFR1 amplification status was determined using FISH analysis (FGFR1/centromere 8 ratio ≥2). Among those receiving end… (full text at CIViC) PMID 31371343 · Drago et al., 2019 · Open in CIViC	civic
FGFR1 Amplification	Erdafitinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID12469 Fibroblast Growth Factor Receptor 1 (FGFR1) amplification is frequently observed in estrogen receptor-positive (ER+) breast cancer and is associated with poor prognosis and resistance to endocrine the… (full text at CIViC) PMID 38603651 · Gong et al., 2024 · Open in CIViC	civic
FGFR1 Amplification	Erdafitinib + Fulvestrant + PalbociclibCombination	Predictive	B	Does Not Support Sensitivity Response	1	submitted	EID12485 Hormone-receptor positive HER2-negative (HR+) breast cancers can harbor alterations in fibroblast growth factor receptors (FGFRs), particularly FGFR1 amplification, which is associated with poor progn… (full text at CIViC) PMID 40627530 · Gonzalez-Ericsson et al., 2025 · Open in CIViC	civic
FGFR1 Amplification	Erdafitinib Regimen	Predictive	B	Supports Sensitivity Response	2	rejected	EID12468 The NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 was an open-label, single-arm, phase II study that required central confirmation of FGFR1–4 amplification in tumors. 18 patients were enrolled, i… (full text at CIViC) PMID 39040443 · Marin et al., 2024 · Open in CIViC	civic
FGFR1 Amplification	Fulvestrant + Palbociclib + RogaratinibCombination	Predictive	D	Supports Sensitivity Response	5	accepted	EID12503 To determine if there is a causal relationship between hormonal blockade (a frequent treatment for tumors in the adjuvant setting) and FGFR1 amplification/overexpression, this study used two non-FGFR1… (full text at CIViC) PMID 33579347 · Mouron et al., 2021 · Open in CIViC	civic
FGFR1 Amplification	Futibatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID12547 Futibatinib is a selective FGFR inhibitor. In this 2020 preclinical study, its antitumor activity was evaluated in cancer cell lines and xenograft models. The antiproliferative activity was assessed … (full text at CIViC) PMID 32973082 · Sootome et al., 2020 · Open in CIViC	civic
FGFR1 Amplification	Infigratinib	Predictive	B	Does Not Support Resistance	2	accepted	EID1909 Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Among the 21 continuously treated (>100mg) patients with breast cancer and FGFR1 amplification (… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
FGFR1 Amplification	Lucitanib	Predictive	B	Supports Sensitivity Response	3	accepted	EID7488 In a phase 1 trial, patients with advanced solid tumors were treated with FGFR1/2, VEGFR1/2/3, and PDGFR inhibitor lucitanib. Among 12 patients with breast cancer harboring FGFR alterations (8 FGFR1 a… (full text at CIViC) PMID 25193991 · Soria et al., 2014 · Open in CIViC	civic
FGFR1 Amplification	Lucitanib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12488 HR+/HER2– breast cancers frequently harbor fibroblast growth factor receptor (FGFR) alterations, and FGFR1 amplification has been linked to poor prognosis and resistance to both endocrine therapy and … (full text at CIViC) PMID 31619444 · Hui et al., 2020 · Open in CIViC	civic
FGFR1 Amplification	Pazopanib	Predictive	C	Supports Sensitivity Response	2	accepted	EID7246 Case report in a HR positive, Her2/neu negative breast cancer patient harboring an FGFR1 amplification. The patient responded to treatment to Pazopanib - including a near CR of brain metastases. Durat… (full text at CIViC) PMID 29223982 · Cheng et al., 2017 · Open in CIViC	civic
FGFR1 Amplification	Pemigatinib	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID12542 The phase 2 FIGHT-207 basket study was designed to evaluate pemigatinib, a selective FGFR inhibitor, in patients with previously treated advanced solid tumors harboring FGFR alterations. Eligible pati… (full text at CIViC) PMID 38710951 · Rodón et al., 2024 · Open in CIViC	civic
FGFR1 Amplification	Lucitanib + RogaratinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	accepted	EID12505 FGFR1 amplification (FGFR1amp) is frequently detected in metastatic breast cancer (MBC), where it is recognized as a generic marker of poor prognosis and most notably, resistance to CDK4/6 inhibitors … (full text at CIViC) PMID 34593528 · Sánchez-Guixé et al., 2022 · Open in CIViC	civic
FGFR1 Amplification	Sunitinib	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID12479 The Targeted Agent and Profiling Utilizing Registry (TAPUR) study is a prospective, phase II, basket trial that aims to evaluate the antitumor activity of commercially available targeted therapies pre… (full text at CIViC) PMID 38354330 · Calfa et al., 2024 · Open in CIViC	civic
FGFR1 Amplification AND ZNF703 Amplification	Letrozole + RibociclibCombination	Predictive	B	Supports Resistance	3	submitted	EID12531 In a cohort of 427 patients from the MONALEESA-2 study, which compared aramotase inhibitor letrozole plus CDK4/6 inhibitor ribociclib vs. letrozole plus placebo in patients with ER+/HER2− advanced bre… (full text at CIViC) PMID 30914635 · Formisano et al., 2019 · Open in CIViC	civic

Malignant Breast Neoplasm21

FGFR1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID12486

PALOMA-3, a phase III, multicenter, double-blind randomized controlled trial enrolled patients with advanced estrogen receptor-positive breast cancer receiving fulvestrant (estrogen receptor antagonis… (full text at CIViC)

PMID 32940689 · O'Leary et al., 2021 · Open in CIViC

civic

FGFR1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID12487

This study aimed to determine the amplification rates of FGFR1, FGFR2, and FGFR3 in breast cancer and evaluate their impact on prognosis. In a cohort of 894 breast cancer patients, FGFR1 amplification… (full text at CIViC)

PMID 32852708 · Erber et al., 2020 · Open in CIViC

civic

FGFR1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID12497

Amplification of FGFR1 is one molecular alteration associated with hormonal resistance and relapse in breast cancer. Using two different patient data cohorts (H12O - patients diagnosed at Hospital 12 … (full text at CIViC)

PMID 33579347 · Mouron et al., 2021 · Open in CIViC

civic

FGFR1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID12532

In a cohort of 100 patients with metastatic breast cancer, FGFR1 Amplification was found in 20 cases via FISH, with 17 cases classified as amplified and three cases as low amplified using published cr… (full text at CIViC)

PMID 32517171 · Bourrier et al., 2020 · Open in CIViC

civic

FGFR1 Amplification

Afimoxifene

Predictive

Supports Resistance

accepted

EID1105

FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1.

PMID 20179196 · Turner et al., 2010 · Open in CIViC

civic

FGFR1 Amplification

Dovitinib

Predictive

Supports Sensitivity Response

accepted

EID1604

Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC)

PMID 23658459 · André et al., 2013 · Open in CIViC

civic

FGFR1 Amplification

Dovitinib

Predictive

Supports Sensitivity Response

accepted

EID12478

Dovitinib, a pan-FGFR small molecular inhibitor, has shown activity in pre-clinical models against FGFR-expressing breast cancer model cell lines, as well as as in a single agent in a phase II clinica… (full text at CIViC)

PMID 28183331 · Musolino et al., 2017 · Open in CIViC

civic

FGFR1 Amplification

Endocrine Drug Therapy + EverolimusCombination

Predictive

Supports Sensitivity Response

accepted

EID12498

In a clinical cohort of patients with HR+/HER2- metastatic breast cancer (n=110), FGFR1 amplification status was determined using FISH analysis (FGFR1/centromere 8 ratio ≥2). Among those receiving end… (full text at CIViC)

PMID 31371343 · Drago et al., 2019 · Open in CIViC

civic

FGFR1 Amplification

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID12469

Fibroblast Growth Factor Receptor 1 (FGFR1) amplification is frequently observed in estrogen receptor-positive (ER+) breast cancer and is associated with poor prognosis and resistance to endocrine the… (full text at CIViC)

PMID 38603651 · Gong et al., 2024 · Open in CIViC

civic

FGFR1 Amplification

Erdafitinib + Fulvestrant + PalbociclibCombination

Predictive

Does Not Support Sensitivity Response

submitted

EID12485

Hormone-receptor positive HER2-negative (HR+) breast cancers can harbor alterations in fibroblast growth factor receptors (FGFRs), particularly FGFR1 amplification, which is associated with poor progn… (full text at CIViC)

PMID 40627530 · Gonzalez-Ericsson et al., 2025 · Open in CIViC

civic

FGFR1 Amplification

Erdafitinib Regimen

Predictive

Supports Sensitivity Response

rejected

EID12468

The NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 was an open-label, single-arm, phase II study that required central confirmation of FGFR1–4 amplification in tumors. 18 patients were enrolled, i… (full text at CIViC)

PMID 39040443 · Marin et al., 2024 · Open in CIViC

civic

FGFR1 Amplification

Fulvestrant + Palbociclib + RogaratinibCombination

Predictive

Supports Sensitivity Response

accepted

EID12503

To determine if there is a causal relationship between hormonal blockade (a frequent treatment for tumors in the adjuvant setting) and FGFR1 amplification/overexpression, this study used two non-FGFR1… (full text at CIViC)

PMID 33579347 · Mouron et al., 2021 · Open in CIViC

civic

FGFR1 Amplification

Futibatinib

Predictive

Supports Sensitivity Response

accepted

EID12547

Futibatinib is a selective FGFR inhibitor. In this 2020 preclinical study, its antitumor activity was evaluated in cancer cell lines and xenograft models. The antiproliferative activity was assessed … (full text at CIViC)

PMID 32973082 · Sootome et al., 2020 · Open in CIViC

civic

FGFR1 Amplification

Infigratinib

Predictive

Does Not Support Resistance

accepted

EID1909

Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Among the 21 continuously treated (>100mg) patients with breast cancer and FGFR1 amplification (… (full text at CIViC)

PMID 27870574 · Nogova et al., 2017 · Open in CIViC

civic

FGFR1 Amplification

Lucitanib

Predictive

Supports Sensitivity Response

accepted

EID7488

In a phase 1 trial, patients with advanced solid tumors were treated with FGFR1/2, VEGFR1/2/3, and PDGFR inhibitor lucitanib. Among 12 patients with breast cancer harboring FGFR alterations (8 FGFR1 a… (full text at CIViC)

PMID 25193991 · Soria et al., 2014 · Open in CIViC

civic

FGFR1 Amplification

Lucitanib

Predictive

Supports Sensitivity Response

submitted

EID12488

HR+/HER2– breast cancers frequently harbor fibroblast growth factor receptor (FGFR) alterations, and FGFR1 amplification has been linked to poor prognosis and resistance to both endocrine therapy and … (full text at CIViC)

PMID 31619444 · Hui et al., 2020 · Open in CIViC

civic

FGFR1 Amplification

Pazopanib

Predictive

Supports Sensitivity Response

accepted

EID7246

Case report in a HR positive, Her2/neu negative breast cancer patient harboring an FGFR1 amplification. The patient responded to treatment to Pazopanib - including a near CR of brain metastases. Durat… (full text at CIViC)

PMID 29223982 · Cheng et al., 2017 · Open in CIViC

civic

FGFR1 Amplification

Pemigatinib

Predictive

Does Not Support Sensitivity Response

accepted

EID12542

The phase 2 FIGHT-207 basket study was designed to evaluate pemigatinib, a selective FGFR inhibitor, in patients with previously treated advanced solid tumors harboring FGFR alterations. Eligible pati… (full text at CIViC)

PMID 38710951 · Rodón et al., 2024 · Open in CIViC

civic

FGFR1 Amplification

Lucitanib + RogaratinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID12505

FGFR1 amplification (FGFR1amp) is frequently detected in metastatic breast cancer (MBC), where it is recognized as a generic marker of poor prognosis and most notably, resistance to CDK4/6 inhibitors … (full text at CIViC)

PMID 34593528 · Sánchez-Guixé et al., 2022 · Open in CIViC

civic

FGFR1 Amplification

Sunitinib

Predictive

Does Not Support Sensitivity Response

accepted

EID12479

The Targeted Agent and Profiling Utilizing Registry (TAPUR) study is a prospective, phase II, basket trial that aims to evaluate the antitumor activity of commercially available targeted therapies pre… (full text at CIViC)

PMID 38354330 · Calfa et al., 2024 · Open in CIViC

civic

FGFR1 Amplification AND ZNF703 Amplification

Letrozole + RibociclibCombination

Predictive

Supports Resistance

submitted

EID12531

In a cohort of 427 patients from the MONALEESA-2 study, which compared aramotase inhibitor letrozole plus CDK4/6 inhibitor ribociclib vs. letrozole plus placebo in patients with ER+/HER2− advanced bre… (full text at CIViC)

PMID 30914635 · Formisano et al., 2019 · Open in CIViC

civic

Malignant Colorectal Neoplasm1
FGFR1 Amplification	Regorafenib	Predictive	C	Supports Sensitivity Response	2	submitted	EID13263 Among 76 patients with refractory metastatic colorectal cancer treated with regorafenib, FGFR1 amplification was identified in three patients (3.9%), and all three achieved a partial response to regor… (full text at CIViC) PMID 33224274 · Lee et al., 2020 · Open in CIViC	civic

Malignant Colorectal Neoplasm1

FGFR1 Amplification

Regorafenib

Predictive

Supports Sensitivity Response

submitted

EID13263

Among 76 patients with refractory metastatic colorectal cancer treated with regorafenib, FGFR1 amplification was identified in three patients (3.9%), and all three achieved a partial response to regor… (full text at CIViC)

PMID 33224274 · Lee et al., 2020 · Open in CIViC

civic

Malignant Lung Neoplasm1
FGFR1 Amplification	Erdafitinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID7954 JNJ-42756493 (erdafitinib) inhibitory effect was tested across a broad panel of lung cancer cell lines. Increased inhibit was associated with FGFR1 amplification. However, not all FGFR1-amplified ce… (full text at CIViC) PMID 28341788 · Perera et al., 2017 · Open in CIViC	civic

Malignant Lung Neoplasm1

FGFR1 Amplification

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID7954

JNJ-42756493 (erdafitinib) inhibitory effect was tested across a broad panel of lung cancer cell lines. Increased inhibit was associated with FGFR1 amplification. However, not all FGFR1-amplified ce… (full text at CIViC)

PMID 28341788 · Perera et al., 2017 · Open in CIViC

civic

Malignant Neoplasm3
FGFR1 Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID685 Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification. However, larger studie… (full text at CIViC) PMID 25171497 · Chang et al., 2014 · Open in CIViC	civic
FGFR1 Amplification OR FGFR2 Amplification OR FGFR3 Amplification OR FGFR4 Amplification	Erdafitinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID12024 In this phase II trial, 35 patients harbouring tumours with FGFR1-4 amplifications were treated with FGFR1-4 inhibitor, erdafitinib. 33 of the 35 patients were eligible and treated, while biopsies wer… (full text at CIViC) PMID 38603651 · Gong et al., 2024 · Open in CIViC	civic
FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion	Fexagratinib	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11675 In this NCI-MATCH trial subprotocol W, 48 patients harbouring FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n=19), or FGFR1 or FGFR3 fusions (n=9) were treated with… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic

Malignant Neoplasm3

FGFR1 Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID685

Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification. However, larger studie… (full text at CIViC)

PMID 25171497 · Chang et al., 2014 · Open in CIViC

civic

FGFR1 Amplification OR FGFR2 Amplification OR FGFR3 Amplification OR FGFR4 Amplification

Erdafitinib

Predictive

Does Not Support Sensitivity Response

submitted

EID12024

In this phase II trial, 35 patients harbouring tumours with FGFR1-4 amplifications were treated with FGFR1-4 inhibitor, erdafitinib. 33 of the 35 patients were eligible and treated, while biopsies wer… (full text at CIViC)

PMID 38603651 · Gong et al., 2024 · Open in CIViC

civic

FGFR1 Amplification OR FGFR2 Mutation OR v::FGFR1 Fusion OR FGFR2 Amplification OR FGFR3 Mutation OR FGFR3::v Fusion

Fexagratinib

Predictive

Does Not Support Sensitivity Response

submitted

EID11675

In this NCI-MATCH trial subprotocol W, 48 patients harbouring FGFR1 or FGFR2 amplification (n = 20), FGFR2 or FGFR3 single-nucleotide variants (n=19), or FGFR1 or FGFR3 fusions (n=9) were treated with… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

Estrogen Receptor-positive Breast Cancer3unmapped disease
FGFR1 Amplification	Fulvestrant + LucitanibCombination	Predictive	B	Supports Sensitivity Response	2	submitted	EID12751 In a neoadjuvant letrozole study of ER+/HER2− breast cancer (n = 72), FGFR1 amplification was enriched in endocrine-resistant tumors (9/21, 43%) versus sensitive (3/40, 7%) and intermediate (1/11, 10%… (full text at CIViC) PMID 28751448 · Formisano et al., 2017 · Open in CIViC	civic
FGFR1 Amplification	Ponatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID1767 In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 valu… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC	civic
FGFR1 Amplification OR FGFR1 Overexpression	Antiestrogen Therapy + CDK4/6 InhibitionCombination	Predictive	D	Supports Resistance	4	accepted	EID12557 In a cell line screen using MCF-7, exogenous expression of FGFR1 confers resistance to fulvestrant and fulvestrant plus ribociclib. In a study using breast cancer cell lines MCF-7 and T47D, overexpres… (full text at CIViC) PMID 30914635 · Formisano et al., 2019 · Open in CIViC	civic

Estrogen Receptor-positive Breast Cancer3unmapped disease

FGFR1 Amplification

Fulvestrant + LucitanibCombination

Predictive

Supports Sensitivity Response

submitted

EID12751

In a neoadjuvant letrozole study of ER+/HER2− breast cancer (n = 72), FGFR1 amplification was enriched in endocrine-resistant tumors (9/21, 43%) versus sensitive (3/40, 7%) and intermediate (1/11, 10%… (full text at CIViC)

PMID 28751448 · Formisano et al., 2017 · Open in CIViC

civic

FGFR1 Amplification

Ponatinib

Predictive

Supports Sensitivity Response

accepted

EID1767

In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 valu… (full text at CIViC)

PMID 22238366 · Gozgit et al., 2012 · Open in CIViC

civic

FGFR1 Amplification OR FGFR1 Overexpression

Antiestrogen Therapy + CDK4/6 InhibitionCombination

Predictive

Supports Resistance

accepted

EID12557

In a cell line screen using MCF-7, exogenous expression of FGFR1 confers resistance to fulvestrant and fulvestrant plus ribociclib. In a study using breast cancer cell lines MCF-7 and T47D, overexpres… (full text at CIViC)

PMID 30914635 · Formisano et al., 2019 · Open in CIViC

civic

HER2 Negative Breast Cancer1unmapped disease
FGFR1 Amplification	Fexagratinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID1991 Eight patients with advanced HER2-negative breast cancer and FGFR1 amplification were evaluated for response to AZD4547. One patient (12.4%) demonstrated a confirmed response to AZD4547. In a preclini… (full text at CIViC) PMID 27179038 · Pearson et al., 2016 · Open in CIViC	civic

HER2 Negative Breast Cancer1unmapped disease

FGFR1 Amplification

Fexagratinib

Predictive

Supports Sensitivity Response

accepted

EID1991

Eight patients with advanced HER2-negative breast cancer and FGFR1 amplification were evaluated for response to AZD4547. One patient (12.4%) demonstrated a confirmed response to AZD4547. In a preclini… (full text at CIViC)

PMID 27179038 · Pearson et al., 2016 · Open in CIViC

civic

Evidence by cancer (41 items)

Clinical significance (0)